After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

Starting today, the mass production or sale of non-approved "semaglutide" drugs is considered illegal under US compounding laws. Novo Nordisk is responding with a special offer for Wegovy ...

With a U.S. Food and Drug Administration ban on copycat semaglutide drugs now in effect, Novo Nordisk is launching a series of initiatives to improve access to authentic versions of its ...

Novo Nordisk is making yet another bet on obesity ... Septerna’s binding site has 80% to 90% sequence similarity across the three receptors, versus 40% to 60% for rival assets.

created by Danish pharmaceutical company Novo Nordisk. The drug soared in popularity by offering a quicker fix to obesity, which is a growing health concern around the globe. Some people also take ...

In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number ...

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide ... Eli Lilly, and Novo Nordisk. Authorship Information ...

Novo Nordisk’s WEGOVY (semaglutide) Overview WEGOVY (semaglutide ... Semaglutide is a GLP-1 analog that shares 94% sequence similarity with human GLP-1. It functions as a GLP-1 receptor agonist ...